A randomized, multi-center, single-use, positive-control open-label study involving 60 patients evaluated local analgesic effect of episil®
oral liquid in cancer patients with oral mucositis induced by chemotherapy/radiotherapy. The patients were randomized in a 1:1 ratio to the episil®
group or KS (a mucoadhesive oral wound rinse, KangsuTM
; Luye Pharmaceutical Co. Ltd, Nanjing, China) group.
The key results of the study:
- The local analgesic effect of episil® within 6 hours post-treatment was significantly better than that of KS
- The analgesic effect of episil® lasted for 6 hours after treatment, which was longer than that of KS
- episil® adhered easily and the film formed rapidly
- There was no significant difference in the incidence rates of adverse events between the two groups.
Read the article